The patent-pending technology is a novel bio-nanomatrix coating, or a bio-engineered material on the nano scale, that mimics natural endothelium, the substance that lines blood vessels. This biocompatibility — the ability to promote the body’s acceptance of implant devices such as heart valves and cardiac stents — can help prevent post-operative tissue scarring that sometimes leads to thrombosis, or blood-flow blockage, among the reported 10 million people who receive implants annually.
’By mimicking natural endothelium, the nanomatrix coating essentially transforms injured blood vessels to a healthy condition at implant sites, and it has great potential for many applications,’ said Dr Ho-Wook Jun, the co-inventor of the technology and UAB assistant professor of biomedical engineering.
’Implanted devices, such as stents, prosthetic heart valves, vascular grafts and indwelling catheters have revolutionised patient care,’ added co-inventor Dr Brigitta Brott, a UAB associate professor of medicine. ’By improving the body’s acceptance of these devices to reduce blood-clot formation and scar-tissue growth, we will greatly improve the quality of life for patients and also potentially drive down healthcare costs by reducing the need for follow-up procedures.’
Brott says US healthcare costs connected to repeat procedures necessitated by clots and blood-flow blockage is estimated at more than $65m (£41m) each year.
The bio-nanomatrix, developed with other interdisciplinary researchers from the UAB schools of medicine and engineering, has now been licensed by the UAB Research Foundation to Endomimetics, a UAB spin-out founded by Jun and Brott. The UAB bio-nanomatrix is claimed to be the only such coating of its kind, although some similar products are in the development pipeline.
Red Bull makes hydrogen fuel cell play with AVL
Formula 1 is an anachronistic anomaly where its only cutting edge is in engine development. The rules prohibit any real innovation and there would be...